Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACRL.L Regulatory News (ACRL)

  • There is currently no data for ACRL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investment in new manufacturing line for Leyland

26 Jun 2017 09:06

RNS Number : 1292J
Accrol Group Holdings PLC
26 June 2017
 

26 June 2017

 

Accrol Group Holdings plc (the "Company" or "Accrol")

Investment in new manufacturing line for Leyland site

 

Accrol Group Holdings plc, the AIM listed leading independent tissue converter, today announces that it has invested €4.5 million in a new tissue converting machine for its recently opened facility in Leyland, Lancashire.

The new machine features the latest technology and will be used in the conversion of a variety of tissue grades, and will have a capacity of 15,000 tonnes or c. £20m sales per annum. Installation and commissioning will be towards the end of FY18.

Accrol opened its 168,000 sq. ft. manufacturing facility in Leyland in April 2017. It has two converting lines installed and operational, with space for a further four converting lines.

Commenting on the investment, Steve Crossley, Accrol's CEO said:

 

"The new converting line will add further production capacity at our Leyland facility and will convert a wide range of product types, particularly at the premium end of the market.

 

"This investment is in line with our growth plans for the business and will ensure that we have the capacity to service, and benefit from, increasing demand from both Major Multiples and the Discount sector."

 

 

For further information please contact:

 

Zeus Capital Limited (Nominated Adviser & Broker) 

 

Dan Bate / Jonathan Sharp

Tel: +44 (0) 161 831 1512

Dominic King / Mike Seabrook / John Goold

Tel: +44 (0) 20 3829 5000

Camarco (Media enquiries) 

 

Jennifer Renwick / Kimberley Taylor

Tel: +44 (0) 203 757 4994

 

Notes to Editors

 

Accrol manufactures toilet rolls, kitchen rolls and facial tissues as well as other tissue products. The Company operates out of c. 900,000 sq. ft. of manufacturing, storage and distribution facilities across Lancashire. Accrol currently manufactures approximately 18 million units per week and supplies some of the UK's largest retailers, providing both Accrol branded and Private Label products (being goods produced under a customer's own brand or under a non-branded or less well-known brand name ("private label")).

The Group's competitive advantage lies in its market positioning, operational process and flexibility. Key components of the business model are:

Production process - The Directors believe the Group obtains a competitive advantage through its model of acquiring and converting the large tissue reels that are Accrol's raw materials ("Parent Reels") as opposed to manufacturing Parent Reels from pulp and recycled fibre and subsequently converting. This requires a lower fixed overhead and provides flexibility in Parent Reel sourcing which allows the Group to take advantage of favourable pricing opportunities and production technology advancements.

 

Technology and converting lines - Accrol has committed capital expenditure of c.£18.2 million in the last three years. The Group currently has 17 converting lines in operation providing capacity of approximately 143,000 tonnes per annum. The Group's operating machinery allows conversion of a wide variety of tissue grades, adding flexibility to the Parent Reel sourcing process and allowing manufacture of a wide range of product types.

 

Manufacturing private label products - The majority of Accrol's products (75 per cent. of revenues in the year ended 30 April 2016) are private label and whilst the Group also develops and supplies branded products, the ability to supply customers with goods under its own brand has allowed penetration into retailers operating in the discount market ("Discounters") and the UK's largest retailers ("Multiples"). Accrol can launch a new private label product within six weeks of instruction from a retailer.

 

Production flexibility - Accrol is able to manufacture toilet rolls, kitchen rolls, facial tissue and certain products used outside a consumer's home ("Away from Home" or "AFH"), providing a "one-stop shop" solution for customers in the tissue market. The ability to produce these goods and supply Multiples, Discounters, local retailers and wholesalers ("Independents") and the AFH market is a competitive advantage and the Directors do not believe any competitors can offer the same flexibility across all of these market channels.

 

Macro-economic impact on raw material prices - There is currently a global over-supply of both pulp and Parent Reels, with additional capacity forecast to be brought on stream through to 2019. As such, Parent Reel prices are currently relatively low and are expected to remain so for the foreseeable future. Low Parent Reel prices allow Accrol to manufacture at a lower cost, enhancing margin and providing pricing flexibility to win new orders. Overcapacity drives increased flexibility of supply and provides Accrol with a choice of pricing and technology when sourcing Parent Reels.

 

Market positioning - Having won a number of contracts with Discounters in recent years and benefitting from the organic growth within this market, the Directors believe Accrol is well positioned to take advantage of the growth in the discount market and Multiples' increased focus on private label products.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGIGDLUGDBGRL
Date   Source Headline
21st Jan 20209:13 amRNSTR-1
20th Jan 20207:00 amRNSRegulatory investigation closed
15th Jan 20207:00 amRNSTR-1
14th Jan 20207:00 amRNSTR-1
7th Jan 20207:00 amRNSHalf Year Results
16th Dec 20197:00 amRNSTR-1
13th Nov 201912:11 pmRNSTR-1
22nd Oct 201911:30 amRNSResult of AGM
17th Oct 20198:00 amRNSVesting of FY2019 Share Option Awards
26th Sep 20198:30 amRNSNotice of AGM
6th Sep 201911:52 amRNSTR-1
3rd Sep 20197:00 amRNSAudited Final Results
10th Jun 20197:00 amRNSTrading Update and Notice of Results
25th Apr 20194:32 pmRNSDirector/PDMR Shareholding
10th Apr 20197:00 amRNSSenior Management Change
27th Mar 201910:20 amRNSRegulatory Investigation Update
11th Feb 20194:35 pmRNSDirector/PDMR Shareholding
6th Feb 20193:03 pmRNSHolding(s) in Company
22nd Jan 20195:15 pmRNSDirector's Dealing
22nd Jan 20199:05 amRNSSecond Price Monitoring Extn
22nd Jan 20199:00 amRNSPrice Monitoring Extension
22nd Jan 20197:01 amRNSHalf Year Results
22nd Jan 20197:00 amRNSBoard Change and Senior Management Appointment
21st Jan 20192:20 pmRNSRegulatory Investigation
10th Jan 20191:35 pmRNSHolding(s) in Company
8th Jan 201911:05 amRNSSecond Price Monitoring Extn
8th Jan 201911:00 amRNSPrice Monitoring Extension
8th Jan 20197:00 amRNSTrading Update
23rd Nov 20187:00 amRNSAccrol Group to present at Mello London
30th Oct 201811:37 amRNSResult of AGM
30th Oct 20187:00 amRNSPDMR Dealings
29th Oct 201811:24 amRNSBoard and Board Committee Changes
10th Oct 20187:00 amRNSAppointment of Non Executive Director
28th Sep 20187:00 amRNSAudited Final Results and Notice of AGM
26th Sep 20187:00 amRNSUnaudited Final Results 2018 and Banking Update
28th Aug 20187:00 amRNSBoard and Senior Management Changes
11th Jul 20187:00 amRNSNotice of Final Results
11th Jul 20187:00 amRNSDirectorate Change
9th Jul 20184:04 pmRNSHolding(s) in Company
18th Jun 20184:39 pmRNSDirector's Dealings
18th Jun 20187:00 amRNSHolding(s) in Company
12th Jun 20183:47 pmRNSDirectors' Dealings
12th Jun 20187:00 amRNSAccrol Leads the Way with Plastic-free Packaging
11th Jun 20187:00 amRNSAppointment of Chief Financial Officer
7th Jun 20187:00 amRNSResult of Open Offer
4th Jun 20182:20 pmRNSHolding(s) in Company
4th Jun 20187:00 amRNSHolding(s) in Company
1st Jun 20188:01 amRNSDirectors' Dealings
1st Jun 20188:00 amRNSPlacing Shares Admitted and Total Voting Rights
31st May 201811:35 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.